The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...
AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...
The FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients ...
The innovative GO chip, developed at the University of Michigan, represents a significant leap in lung cancer treatment by ...
Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer ...
KEYTRUDA (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives ...
The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a HER2-directed antibody-drug conjugate for certain patients with metastatic breast ...
The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly statistically significant and clinically meaningful” improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback